Acromegaly - Causes Symptoms Complications Diagnosis Treatment Prognosis
Acromegaly (Greek-enlargements of the extremities) is a hormonal disorder resulting from excessive production of the growth hormone by the pituitary gland after puberty, often referred as gigantism.
Acromegaly (Greek-enlargements of the extremities) is a hormonal disorder resulting from excessive production of the growth hormone by the pituitary gland after puberty, often referred as gigantism.
‘Acromegaly progression can result in significant health problems such as diabetes mellitus, hypertension, cardiovascular disease, sleep apnea, carpal tunnel syndrome, and spinal cord compression.’
Tweet it Now
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, states: “The majority of the diagnosed prevalent cases of acromegaly in the 7MM are assumed to occur in men and women ages 40–69 years, which, in this study, is driven by a higher proportion of the population being in this age group. Acromegaly is more prevalent in women, who present at an older age with longer diagnostic delay. At presentation, women have a greater growth hormone level compared to men. Among acromegaly patients, the quality of life is more negatively affected by women both before and after treatment.”Among the 7MM, the United States is expected to have the highest number of diagnosed prevalent cases of acromegaly with 26,549 cases in 2019 and growing at an AGR of 1.18 percent (2019-2029), followed by Italy (4,005 cases) and Germany (3,354 cases).
Source-Medindia
Scientists Recommend Tumor Removal as First-Line Treatment for Acromegaly
The Endocrine Society has issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of acromegaly, a rare condition caused by excess growth hormone in the blood.
The Endocrine Society has issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of acromegaly, a rare condition caused by excess growth hormone in the blood.
Signifor LAR Therapy Controls Acromegaly Better: Novartis
Swiss drug maker Novartis said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.
Swiss drug maker Novartis said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.
Woman Suffering from Gigantism Finally Stops Growing for the First Time in a Decade
A 33-year old woman in Las Vegas who is suffering from gigantism revealed that she has finally stopped growing for the first time in 10 years.
A 33-year old woman in Las Vegas who is suffering from gigantism revealed that she has finally stopped growing for the first time in 10 years.
